miophthalmology products

Sophi Phaco System

In January, Rayner officially acquired This AG – the manufacturer of the
Sophi Phaco System – and is relaunching the Sophi System in the Australian market.

Sophi redefines the requirements of a perfect phacoemulsification system by focussing on the points of view of the surgeon and the surgical team.

The result is a high-end device that sets new standards in mobility, simplicity, and safety.

Sophi is the first completely wireless phacoemulsification system providing ease of handling in the operating theatre. It opens new avenues in safety with an intraocular pressure control pump that is designed for high chamber stability.

These combined benefits facilitate simpler, safer, and faster operating procedures.

Contact: Rayner (AUS) 02 9044 1221

RetinaVue 100 Pro

The Welch Allyn RetinaVue 100 Pro from Baxter is designed for healthcare providers and eye specialists who need great image quality and portability.

The RetinaVue 100 Pro is designed to deliver high-quality retinal images to primary care providers and eye care professionals who provide diabetic retinal exams. With touchless auto-focus and image capture, the imager’s ease of use and lightweight, portable design make it well suited for use across clinics and at the bedside – at a fraction of the price of desktop cameras.

Contact: Welch Allyn (AUS) 02 9562 0900

CSO Cobra+

Cobra Plus from CSO is a non-mydriatic digital retinal camera that combines all the necessary functions for fast and accurate retinal screening. It provides comprehensive retinal profiles and the precise health indicators of every analysed retinal area, useful for the diagnosis and follow-up of macular degeneration and degenerative hereditary retinal diseases. On a single screen, the CSO software can display multiple wavelength images from the Cobra+. It can display the original image, infrared image, red-free image, as well as the choroidal, vascular and nerve fibre images, for in-depth retina examinations. An AVR tool is also available to measure the ratio between the branch arteriolar-venous diameter, used to detect early signs of cardiovascular issues. The CSO Cobra includes infrared meibography, allowing you to screen patients for meibomian gland atrophy.

Visit: eyetek.com.au

Cirrus 6000 with Angioplex OCT Angiography (RIGHT)

ZEISS Cirrus AngioPlex optical coherence tomography angiography (OCTA) ushers in a new era of eye care with non-invasive imaging of retinal microvasculature, taking diabetic eye disease management and treatment planning to the next level.

For patients with diabetic retinopathy, AngioPlex OCTA can help highlight early signs of diabetic changes through quantitative examination of the foveal avascular zone (FAZ) and instances of microaneurysms that may not be clearly demonstrated on conventional OCT. ZEISS Cirrus OCTA is Forum compatible, allowing the clinician the ability to overlay the OCTA data cube over the ZEISS Clarus true colour ultra-widefield image and create a full analysis in a single screen. This also provides a clear patient education visualisation to assist in the initial assessment and treatment of diabetic eye disease.

Contact: ZEISS Account Manager

Visionix VX650

The Visionix VX650 is a cutting-edge device that can help with early diagnosis and effective ocular disease management. Its fundus camera helps detect and document diabetic retinopathy, including vascular abnormalities, haemorrhages, and neovascularisation, allowing eye care providers to ensure patients receive the care they need before permanent vision loss occurs.

Other notable features include:

• Dry eye syndrome assessment and documentation,
• Corneal topographical mapping,
• Keratometry and central corneal thickness measurements,
• Intraocular pressure, with and without pachymetry correction, and
• Fundus analysis with non-mydriatic imaging.

Contact: Opticare info@opticare.com.au

iCare Eidon Ultra-Widefield

Experience the power of TrueColor Confocal technology with the iCare Eidon ultra-widefield. View high resolution images of the retina with incredible clarity and natural colours. It captures 1,200 images of the retina in a single shot and even up to 2,000 with mosaics, allowing for a high degree of peripheral visualisation. This provides a significant advantage in early detection and monitoring of diabetic eye disease
and several retinal pathologies.

The iCare Eidon is easy to use with its automated imaging process that captures images even through media opacities and quick flash exposure. Besides the TrueColor confocal images, it enables the acquisition of ultra-widefield infrared, autofluorescence, and fluorescein angiography images.

Contact: Designs for Vision (AUS) 1800 225 307

Vabysmo

Vabysmo (faricimab) is the only bispecific antibody registered on the Australian Register of Therapeutic Goods (ARTG) for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).1,2

Vabysmo is listed also on the Pharmaceutical Benefits Scheme (PBS) for nAMD and DMO.3

This intravitreal treatment works on two distinct pathways, specifically recognising and blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF).1 After four initial four-weekly loading doses, the frequency of ongoing injections may be extended up to every 16 weeks based on the patient’s anatomic and/or visual outcomes.1,4,5

Contact: Roche Account Manager

Please review the Product Information before prescribing, available at: roche-australia.com/productinfo/vabysmo. Vabysmo ▼ is listed on the PBS for nAMD and DMO. Refer to PBS Schedule for full authority information. ▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at tga.gov.au/reporting-problems.

For information on indications, contraindications, systemic effects, concomitant use of other anti-VEGF, withholding treatment, use during pregnancy, and adverse effects refer to page 17 of this issue of mivision. Full PI is available at: roche-australia.com/productinfo/vabysmo.

M-AU-00002420. Prepared Mar24.

References
1. Vabysmo Approved Product Information, available at roche-australia.com/productinfo/vabysmo [accessed May 2024].
2. Australian Government Department of Health and Aged Care. Australian Register of Therapeutic Goods (ARTG), available at: tga.gov.au/resources/artg [accessed Jan 2023].
3. Department of Health. Pharmaceutical Benefits Scheme. Available at: pbs.gov.au.
4. Heier, J.S., Khanani, A.M., Wong, T.Y. et al.; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): Two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 Feb 19;399(10326):729–740. DOI: 10.1016/S0140-6736(22)00010-1.
5. Wykoff, C.C., Abreu, F., Tadayoni, R., et al.; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials. Lancet. 2022 Feb 19;399(10326):741–755. DOI: 10.1016/S0140-6736(22)00018-6.

Eylea

Eylea (aflibercept) binds to vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PLGF) proteins.1

Eylea is listed on the Australian Pharmaceutical Benefits Scheme for five indications in adults: neovascular age-related macular degeneration; visual impairment due to macular oedema secondary to central retinal vein occlusion and branch retinal vein occlusion; diabetic macular oedema; and visual impairment due to myopic choroidal neovascularisation.1,2

Evidence for Eylea is based on randomised controlled trials, real-world, and post-marketing experience, in addition to more than eight million patient-years’ exposure.1, 3-10

Contact: Bayer Account Manager

PBS Information: Authority required for the treatment of wet age-related macular degeneration, diabetic macular oedema, central retinal vein occlusion and branch retinal vein occlusion, myopic choroidal neovascularisation. Refer to PBS schedule for full Authority Required information.

Please refer to the Product Information before prescribing. Approved PI available by scanning the QR code or upon request
from Bayer Medical Information on (AUS) 1800 008 757. Prepared March 2024. PP-EYL-AU-0884-1

M-AU-00002420. Prepared Mar24.

References
1. Eylea Australian Approved Product Information.
2. Pharmaceutical Benefits Scheme: pbs.gov.au.
3. Lukic, M., Williams, G., Rajendram, R., et al., Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes. Eur J Ophthalmol. 2021 May;31(3):1201–1207. DOI: 10.1177/1120672120925034.
4. Eleftheriadou, M., Gemenetzi, M., Patel, P.J., et al., Three-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Evidence from a clinical setting. Ophthalmol Ther. 2018 Dec;7(2):361–368. DOI: 10.1007/s40123-018-0139-5.
5. Traine, P.G., Pfister, I.B., Garweg, J.G., et al., Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a "treat-and-extend" regimen. Ophthalmol Retina. 2019 May;3(5):393–399. DOI: 10.1016/j.oret.2019.01.018.
 6. Sheu, S.J., Yang, C.H., Chen SJ. et al., One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema. J Chin Med Assoc. 2022 Feb 1;85(2):246–251. DOI: 10.1097/JCMA.0000000000000680.
7. Kim, Y.C., Shin, J.P., Lee, J.E., Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema. Sci Rep. 2020 Dec 16;10(1):22030. DOI: 10.1038/s41598-020-78954-3.
8. Hirano, T., Toriyama, Y., Takamura, Y. et al., Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema. Sci Rep 11, 4488 (2021). DOI: 10.1038/s41598-021-83811-y.
9. Ohji, M., Takahashi, K., Terano, Y. et al., ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: A randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173–1187. DOI:10.1007/s12325-020-01236-x. 10. Eylea. Data on file. January 2023(v1.0).